Literature DB >> 11141640

Sjögren syndrome.

K F Tabbara1, C L Vera-Cristo.   

Abstract

Sjögren syndrome is a chronic systemic disease characterized by polyglandular tissue destruction leading to keratoconjunctivitis sicca (KCS) and xerostomia. Patients with primary Sjögren syndrome show evidence of KCS and xerostomia, whereas patients with secondary Sjögren syndrome suffer from KCS, xerostomia, and an autoimmune disease, most commonly rheumatoid arthritis. Certain factors cause autoimmune dysregulation leading to destruction of the acinar cells and ductal epithelia with subsequent dry eyes and dry mouth. Activated lymphocytes in patients with autoimmune diseases appear to have selective homing into the lacrimal and salivary glands leading to tissue damage. Understanding the factors involved in the immune dysregulation may improve our diagnostic and therapeutic approaches in Sjögren syndrome. Current therapeutic measures include means to increase secretion, relieve symptoms, and repair damage of the ocular surface.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11141640     DOI: 10.1097/00055735-200012000-00011

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  7 in total

1.  Small-molecule activators of TMEM16A, a calcium-activated chloride channel, stimulate epithelial chloride secretion and intestinal contraction.

Authors:  Wan Namkung; Zhen Yao; Walter E Finkbeiner; A S Verkman
Journal:  FASEB J       Date:  2011-08-11       Impact factor: 5.191

2.  Pseudotumor cerebri associated with Sjögren's syndrome.

Authors:  Dinu Stanescu; Bahram Bodaghi; Du Le Thi Huong; Dan Milea; B Goulet-Salmon; Jean-Charles Piette; Phuc LeHoang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-03-15       Impact factor: 3.117

3.  Patients with non-Sjögren's sicca report poorer general and oral health-related quality of life than patients with Sjögren's syndrome: a cross-sectional study.

Authors:  B Tashbayev; T Garen; Ø Palm; X Chen; B B Herlofson; A Young; L H Hove; M Rykke; P B Singh; L A Aqrawi; Ø A Utheim; T P Utheim; J L Jensen
Journal:  Sci Rep       Date:  2020-02-07       Impact factor: 4.379

4.  Combined Low-Level Light Therapy and Intense Pulsed Light Therapy for the Treatment of Dry Eye in Patients with Sjögren's Syndrome.

Authors:  Matteo Di Marino; Paola Conigliaro; Francesco Aiello; Claudia Valeri; Clarissa Giannini; Raffaele Mancino; Stella Modica; Carlo Nucci; Roberto Perricone; Massimo Cesareo
Journal:  J Ophthalmol       Date:  2021-06-10       Impact factor: 1.909

5.  Identification of ICF categories relevant for nursing in the situation of acute and early post-acute rehabilitation.

Authors:  Martin Mueller; Christine Boldt; Eva Grill; Ralf Strobl; Gerold Stucki
Journal:  BMC Nurs       Date:  2008-02-18

Review 6.  The immune factors involved in the pathogenesis, diagnosis, and treatment of Sjogren's syndrome.

Authors:  Yi-fan Huang; Qian Cheng; Chun-miao Jiang; Shu An; Lan Xiao; Yong-chao Gou; Wen-jing Yu; Lei Lei; Qian-ming Chen; Yating Wang; Jun Wang
Journal:  Clin Dev Immunol       Date:  2013-07-09

Review 7.  Ocular findings in systemic lupus erythematosus.

Authors:  Samir S Shoughy; Khalid F Tabbara
Journal:  Saudi J Ophthalmol       Date:  2016-02-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.